Orthofix won't sell fixation lines, looks to strengthen ortho unit instead:
This article was originally published in Clinica
Executive Summary
Orthofix International said it is holding on to its external and internal bone fixation products, less than two months after announcing it was looking for buyers for the business. Instead, the company said it will look to free up more cash by tightening operating costs and maximising the value of its orthopaedic business. Growth in Orthofix's orthopaedics business in 2007 was stymied by declining sales of external fixation devices, which fell 11%. Internal fixation sales, on the other hand, soared 48%, aided by the introduction of new products. Orthofix, headquartered in the Netherlands, had announced in February that it was looking to sell its orthopaedic fixation products to reduce debt and invest in its core spine business.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.